On the incorporation of chemical-specific information in risk assessment

Toxicology Letters

Volumn 180, Issue 2, 2008, Pages 100-109

  Clewell III, Harvey J ^a   Andersen, Melvin E ^a   Blaauboer, Bas J ^b  

^a HAMNER INSTITUTES FOR HEALTH SCIENCES   (United States)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Biokinetics; Mode of action; PBPK; Physiological modelling; Risk assessment

Indexed keywords

CARCINOGEN; DICHLOROMETHANE;

ADIPOSE TISSUE; ARTICLE; BODY WEIGHT; CONCENTRATION RESPONSE; DOSE RESPONSE; EVALUATION; EXPOSURE; HAZARD ASSESSMENT; HUMAN; LIVER METABOLISM; LUNG ALVEOLUS; LUNG BLOOD FLOW; MATHEMATICAL AND STATISTICAL PROCEDURES; MATHEMATICAL MODEL; MUSCLE TISSUE; NONHUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; SCIENTIST; TISSUE PERFUSION; TOXICOKINETICS;

ANIMALS; CHEMISTRY; HISTORY, 18TH CENTURY; HISTORY, 20TH CENTURY; HUMANS; MODELS, BIOLOGICAL; MODELS, STATISTICAL; PHARMACOKINETICS; RISK ASSESSMENT; RISK REDUCTION BEHAVIOR; TOXICOLOGY;

EID: 48649087320     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxlet.2008.06.002     Document Type: Article

References (76)

1. Allen B.C., Covington T.R., and Clewell H.J. Investigation of the impact of pharmacokinetic variability and uncertainty on risks predicted with a pharmacokinetic model for chloroform. Toxicology 111 (1996) 289-303
2. Andersen M.E. Saturable metabolism and its relation to toxicity. Crit. Rev. Toxicol. 9 (1981) 105-150
3. Andersen M.E., Clewell H.J., Gargas M.L., Smith F.A., and Reitz R.H. Physiologically-based pharmacokinetics and the risk assessment process for methylene chloride. Toxicol. Appl. Pharmacol. 87 (1987) 185-205
4. Andersen M.E., Clewell H.J., Gargas M.L., MacNaughton M.G., Reitz R.H., Nolan R.J., and McKenna M.J. Physiologically based pharmacokinetic modeling with dichloromethane, its metabolite carbon monoxide, and blood carboxyhemoglobin in rats and humans. Toxicol. Appl. Pharmacol. 108 (1991) 14-27
5. Andersen M.E., Clewell H.J., and Frederick C.B. Applying simulation modeling to problems in toxicology and risk assessment-a short perspective. Toxicol. Appl. Pharmacol. 133 (1995) 181-187
6. Andersen M.E., Clewell H.J., and Krishnan K. Tissue dosimetry, pharmacokinetic modeling, and interspecies scaling factors. Risk Anal. 15 (1995) 533-537
7. Andersen M.E., Gearhart J.M., and Clewell III H.J. Pharmacokinetic data needs to support risk assessments for inhaled and ingested manganese. NeuroToxicology 20 2-3 (1999) 161-172
8. Andersen M.E., Dennison J.E., Thomas R.S., and Conolly R.B. New directions in incidence-dose modeling. Trends Biotechnol. 23 3 (2005) 122-127
9. Barlow S.M., Greig J.B., Bridges J.W., Carere A., Carpy A.J.M., Galli C.L., Kleiner J., Knudsen I., Koeter H.B.W.M., Levy L.S., Madsen C., Mayer S., Narbonne J.-F., Pfannkuch F., Prodanchuk M.G., Smith M.R., and Steinberg P. Hazard identification of methods of animal-based toxicology. Food Chem. Toxicol. 40 (2002) 145-191
10. Barton H.A. Computational pharmacokinetics during developmental windows of susceptibility. J. Toxicol. Environ. Health A 68 11-12 (2005) 889-900
11. Binswanger H.C., and Smith K.R. Paracelsus and Goethe: founding fathers of environmental health. Bull. World Health Org. 78 9 (2000) 1162-1165
12. Bischoff K.B. Physiologically based pharmacokinetic modeling. National Research Council. Pharmacokinetics in Risk Assessment. Drinking Water and Health vol. 8 (1987), National Academy Press, Washington, DC 36-61
13. Blaauboer B.J. The integration of data on physico-chemical properties, in vitro-derived toxicity data and physiologically based kinetic and dynamic modelling as a tool in hazard and risk assessment. A commentary. Toxicol. Lett. 138 1-2 (2003) 161-171
14. Boobis A.R., Cohen S.M., Dellarco V., McGregor D., Meek M.E., Vickers C., Willcocks D., and Farland W. IPCS framework for analyzing the relevance of a cancer mode of action for humans. Crit. Rev. Toxicol. 36 10 (2006) 781-792
15. Boobis A.R., Doe J.E., Heinrich-Hirsch B., Meek M.E., Munn S., Ruchirawat M., Schlatter J., Seed J., and Vickers C. IPCS framework for analyzing the relevance of a noncancer mode of action for humans. Crit. Rev. Toxicol. 38 2 (2008) 87-96
16. Clark L.H., Setzer R.W., and Barton H.A. Framework for evaluation of physiologically based pharmacokinetic models for use in safety or risk assessment. Risk Anal. 24 (2004) 1697-1718
17. Clement D.S., and Tatman J.A. Dealing with uncertainty in chemical risk assessment. Proceedings of the 18th Conference on Toxicology. Harry G. Armstrong Aerospace Medical Research Laboratory, Dayton, OH AAMRL-TR-90-032, November 1988 (1990)
18. Clewell H.J. The use of physiologically based pharmacokinetic modeling in risk assessment: a case study with methylene chloride. In: Olin S., Farland W., Park C., Rhomberg R., Scheuplein L., Starr T., and Wilson J. (Eds). Low-Dose Extrapolation of Cancer Risks: Issues and Perspectives (1995), ILSI Press, Washington, DC
19. Clewell H.J., and Andersen M.E. Risk assessment extrapolations and physiological modeling. Toxicol. Ind. Health 1 (1985) 111-131
20. Clewell H.J., and Andersen M.E. Dose species and route extrapolation using physiologically based pharmacokinetic models. Drinking Water and Health vol. 8 (1987), National Research Council, Washington, DC 159-182
21. Clewell H.J., and Andersen M.E. Biologically motivated models for chemical risk assessment. Health Phys. 57 Suppl. 1 (1989) 129-137
22. Clewell H.J., Lee T., and Carpenter R.L. Sensitivity of physiologically-based pharmacokinetic models to variation in model parameters: methylene chloride. Risk Anal. 14 (1994) 521-531
23. Clewell R.A., Merrill E.A., Gearhart J.M., Robinson P.J., Sterner T.R., Mattie D.R., and Clewell III H.J. Perchlorate and radioiodide kinetics across life-stages in the human: Using PBPK models to predict dosimetry and thyroid inhibition and sensitive subpopulations based on developmental stage. J. Toxicol. Environ. Health A 70 5 (2007) 408-428
24. Corley R.A., Bormett G.A., and Ghanayem B.I. Physiologically based pharmacokinetics of 2-butoxyethanol and its major metabolite, 2-butoxyacetic acid, in rats and humans. Toxicol. Appl. Pharmacol. 129 (1994) 61-79
25. Corley R.A., Markham D.A., Banks C., Delorme P., Masterman A., and Houle J.M. Physiologically based pharmacokinetics and the dermal absorption of 2-butoxyethanol vapour by humans. Fundam. Appl. Toxicol. 39 (1997) 120-130
26. Covington T.R., Gentry P.R., VanLandingham C.B., Andersen M.E., Kester J.E., and Clewell H.J. The use of Markov chain Monte Carlo uncertainty analysis to support a public health goal for perchloroethylene. Reg. Tox. Pharm. 47 1 (2007) 1-18
27. DeWoskin R.S., Barone S., Clewell H.J., and Setzer R.W. Improving the development and use of biologically based dose response models (BBDR) in risk assessment. Hum. Ecol. Risk Assess. 7 (2001) 1091-1120
28. Dill J.A., Lee K.M., Bates D.J., Anderson D.J., Johnson R.E., Chou B.J., Burka L.T., and Roycroft J.H. Toxicokinetics of inhaled 2-butoxyethanol and its major metabolite, 2-butoxyacetic acid, in F344 rats and B6C3F1 mice. Toxicol. Appl. Pharmacol. 153 2 (1998) 227-242
29. Doull J. In: Clewell H.J. (Ed). Conference on Chemical Risk Assessment in the Department of Defense (DoD): Science, Policy, and Practice. Dayton, OH, April, 1991 (1992), American Conference of Government Industrial Hygienists, Cincinnati, OH Plenary presentation
30. Dybing E., Doe J., Groten J., Kleiner J., O'Brien J., Renwick A.G., Schlatter J., Steinberg P., Tritscher A., Walker R., and Younes M. Hazard characterisation of chemicals in food and diet-dose response, mechanisms and extrapolation issues. Food Chem. Toxicol. 40 (2002) 237-282
31. Edler L., Poirier K., Dourson M., Kleiner J., Mileson B., Nordmann H., Renwick A., Slob W., Walton K., and Wuertzen G. Mathematical modelling and quantitative methods. Food Chem. Toxicol. 40 (2002) 283-326
32. Eisenbrand G., Pool-Zobel B., Baker V., Balls M., Blaauboer B.J., Boobis A., Carere A., Kevekordes S., Lhuguenot J.-C., Pieters R., and Kleiner J. Methods of in vitro toxicology. Food Chem. Toxicol. 40 (2002) 193-236
33. el-Masri H.A., Thomas R.S., Benjamin S.A., and Yang R.S. Physiologically based pharmacokinetic/pharmacodynamic modeling of chemical mixtures and possible applications in risk assessment. Toxicology 105 (1995) 275-282
34. Fiserova-Bergerova V. Modeling of Inhalation Exposure to Vapors: Uptake Distribution and Elimination vol. 2 (1983), CRC Press, Boca Raton, FL p. 108-130
35. Fisher J.W., Whittaker T.A., Taylor D.H., Clewell H.J., and Andersen M.E. Physiologically based pharmacokinetic modeling of the pregnant rat: a multiroute exposure model for trichlorethylene and its metabolite, trichloroacetic acid. Toxicol. Appl. Pharmacol. 99 (1989) 395-414
36. Fisher J.W., Whittaker T.A., Taylor D.H., Clewell H.J., and Andersen M.E. Physiologically based pharmacokinetic modeling of the lactating rat and nursing pup: a multiroute exposure model for trichlorethylene and its metabolite, trichloroacetic acid. Toxicol. Appl. Pharmacol. 102 (1990) 497-513
37. Gearhart J.M., Jepson G.W., Clewell III H.J., Andersen M.E., and Conolly R.B. Physiologically based pharmacokinetic model for the inhibition of acetylcholinesterase by organophosphate esters. Environ. Health Perspect. 102 (1994) 51-60
38. Gentry P.R., Hack C.E., Haber L., Maier A., and Clewell III H.J. An approach for the quantitative consideration of genetic polymorphism data in chemical risk assessment: examples with warfarin and parathion. Toxicol. Sci. 70 (2002) 120-139
39. Gerlowski L.E., and Jain R.K. Physiologically based pharmacokinetic modeling: principles and applications. J. Pharm. Sci. 72 (1983) 1103-1126
40. Ghanayem B.I., Sanchez I.M., and Matthews H.B. Development of tolerance to 2-butoxyethanol-induced hemolytic anemia and studies to elucidate the underlying mechanisms. Toxicol. Appl. Pharmacol. 112 2 (1992) 198-206
41. Gilbert, S.G., 2007. Milestones and discoveries in the renaissance. A small dose of ... http://www.asmalldoseof.org/historyoftox/renaissance.htox.php.
42. Hack C.E., Covington T.R., Lawrence G., Shipp A.M., Gentry P.R., Yager J.A., and Clewell III H.J. A pharmacokinetic model of the intracellular dosimetry of inhaled nickel. J. Toxicol. Environ. Health A 70 (2007) 445-464
43. Hawkins N.C., and Graham J.D. Expert scientific judgment and cancer risk assessment: a pilot study of pharmacokinetic data. Risk Anal. 8 4 (1988) 615-625
44. Health Council of the Netherlands (HCN), 2001. Toxicity testing: a more efficient approach. Publication 2001/24E, The Hague, Netherlands. Available from: http://www.gr.nl/adviezen.php.
45. Health Canada. Priority Substances List Assessment Report: 2-Butoxyethanol (2003). http://www.hc-sc.gc.ca/ewh-semt/alt_formats/hecs-sesc/pdf/pubs/contaminants/psl2-lsp2/2_butoxyethanol/2_butoxyethanol_e.pdf Available from: http://www.hc-sc.gc.ca/ewh-semt/alt_formats/hecs-sesc/pdf/pubs/contaminants/psl2-lsp2/2_butoxyethanol/2_butoxyethanol_e.pdf.
46. Hill A.B. The environment and disease: association or causation?. Proc. R. Soc. Med. 58 (1965) 295-300
47. Himmelstein K.J., and Lutz R.J. A review of the application of physiologically based pharmacokinetic modeling. J. Pharmacokinet. Biopharm. 7 (1979) 127-145
48. IPCS. Chemical-specific Adjustment Factors for Interspecies Differences and Human Variability: Guidance Document for Use of Data in Dose/Concentration-Response Assessment (2005), World Health Organization, Geneva. http://www.who.int/ipcs/methods/harmonization/areas/uncertainty/en/index.html Available at: http://www.who.int/ipcs/methods/harmonization/areas/uncertainty/en/index.html
49. Johanson G., and Filser J.G. A physiologically based pharmacokinetic model for butadiene and its metabolite butadiene monoxide in rat and mouse and its significance for risk extrapolation. Arch. Toxicol. 67 (1993) 151-163
50. Johanson G., and Johnsson S. Gas chromatographic determination of butoxyacetic acid in human blood after exposure to 2-butoxyethanol. Arch. Toxicol. 65 5 (1991) 433-435
51. Kroes R., Muller D., Lambe J., Lowik M.R.H., van Klaveren J., Kleiner J., Massey R., Mayer S., Urieta I., Verger P., and Visconti A. Assessment of intake from the diet. Food Chem. Toxicol. 40 (2002) 327-385
52. Lee K.M., Dill J.A., Chou B.J., and Roycroft J.H. Physiologically based pharmacokinetic model for chronic inhalation of 2-butoxyethanol. Toxicol. Appl. Pharmacol. 153 2 (1998) 211-226
53. Leung H.W. Development and utilization of physiologically based pharmacokinetic models for toxicological applications. J. Toxicol. Environ. Health 32 (1991) 247-267
54. National Academy of Science (NAS). Risk Assessment in the Federal Government: Managing the Process (1983), National Academy Press, Washington, DC
55. National Academy of Science (NAS). Toxicity Testing in the Twenty First Century: A Vision and a Strategy (2007), National Academy Press, Washington, DC
56. Nong A., Teeguarden J.G., Clewell III H.J., Dorman D.C., and Andersen M.E. Pharmacokinetic modeling of manganese. IV. Assessing factors that contribute to brain accumulation during inhalation exposures. J. Toxicol. Environ. Health A 71 (2007) 413-426
57. O'Flaherty E.J. Modeling: an introduction. Pharmacokinetics in Risk Assessment. Drinking Water and Health vol. 8 (1987), National Academy Press, Washington, DC 27-35
58. O'Flaherty E.J. Interspecies conversion of kinetically equivalent doses. Risk Anal. 9 (1989) 587-598
59. Office of Management and Budget (OMB), 2002. Guidelines for Ensuring and Maximizing the Quality, Objectivity, Utility, and Integrity of Information Disseminated by Federal Agencies. 67 FR 8452.
60. Reddy M.B., Yang R.S.H., Clewell III H.J., and Andersen M.E. Physiologically Based Pharmacokinetic Modeling: Science and Applications (2005), John Wiley, Hoboken, NJ
61. Reitz R.H., Mendrala A.L., Corley R.A., Quast J.F., Gargas M.L., Andersen M.E., Staats D.A., and Conolly R.B. Estimating the risk of liver cancer associated with human exposures to chloroform using physiologically based pharmacokinetic modeling. Toxicol. Appl. Pharmacol. 105 (1990) 443-459
62. Renwick A.G. Data derived safety factors for the evaluation of food additives and environmental contaminants. Food Addit. Contam. 10 (1993) 275-305
63. Renwick A.G., and Lazarus N.R. Human variability and noncancer risk assessment: an analysis of the default uncertainty factor. Regul. Toxicol. Pharmacol. 27 1 (1998) 3-20
64. Renwick A.G., and Walton K. The use of surrogate endpoints to assess potential toxicity in humans. Toxicol. Lett. 120 (2001) 97-110
65. Renwick A.G., Barlow S.M., Hertz-Picciotto I., Boobis A.R., Dybing E., Edler L., Eisenbrand G., Greig J.B., Kleiner J., Lambe J., Müller D.J.G., Smith M.R., Tritscher A., Tuijtelaars S., van den Brandt P.A., Walker R., and Kroes R. Risk characterisation of chemicals in food and diet. Food Chem. Toxicol. 41 (2003) 1211-1271
66. Rodricks J.V., Brown S.L., Putzrath R., and Turnbull D. An industry perspective: invited presentation on use of risk information in regulation of carcinogens. In: Griffin H.E., and North D.W. (Eds). Proceedings of a One-Day Workshop on Determination of No Significant Risk Under Proposition 65. December 16, 1987 (1987) 18-41
67. Sonich-Mullin C., Fielder R., Wiltse J., Baetcke K., Dempsey J., Fenner-Crisp P., Grant D., Hartley M., Knaap A., Kroese D., Mangelsdorf I., Meek E., Rice J.M., and Younes M. IPCS conceptual framework for evaluating a mode of action for chemical carcinogenesis. Reg. Toxicol. Pharmacol. 34 2 (2001) 146-152
68. Stone R. Counting the cost of London's killer smog. Science 298 5601 (2002) 2106-2107
69. Tan Y.M., Butterworth B.E., Gargas M.L., and Conolly R.B. Biologically motivated computational modeling of chloroform cytolethality and regenerative cellular proliferation. Toxicol. Sci. 75 1 (2003) 192-200
70. Tan Y.-M., Liao K.H., Conolly R.B., Blount B.C., Mason A.M., and Clewell H.J. Use of a physiologically based pharmacokinetic model to identify exposures consistent with human biomonitoring data for chloroform. J. Toxicol. Environ. Health A 69 (2006) 1727-1756
71. Teorell T. Kinetics of distribution of substances administered to the body. I. The extravascular mode of administration. Arch. Int. Pharmacodyn. 57 (1937) 205-225
72. Teorell T. Kinetics of distribution of substances administered to the body. I. The intravascular mode of administration. Arch. Int. Pharmacodyn. 57 (1937) 226-240
73. U.S. Environmental Protection Agency (USEPA). Methods for Derivation of Inhalation Reference Concentrations and Application of Inhalation Dosimetry EPA/600/8-90/066F (1994), Office of Health and Environmental Assessment, USEPA, Washington, DC
74. U.S. Environmental Protection Agency (USEPA). Toxicological Review of Boron and Compounds in Support of Summary Information on the Integrated Risk Information System (IRIS). EPA 635/04/052 (2002), USEPA, Washington, DC
75. U.S. Environmental Protection Agency (USEPA). Guidelines for Carcinogen Risk Assessment. EPA/630/P-03/001B. Risk Assessment Forum (2005), USEPA, Washington, DC
76. van den Brandt P., Voorrips L., Hertz-Picciotto I., Shuker D., Boeing H., Speijers G., Guittard C., Kleiner J., Knowles M., Wolk A., and Goldbohm A. The contribution of epidemiology. Food Chem. Toxicol. 40 (2002) 387-424